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Crohn’s disease (CD) is a chronic inflammatory disorder, characterized by cytokine imbalance and transcription signaling pathways
activation. In addition, the increase of mesenteric adipose tissue (MAT) near the affected intestinal area is a hallmark of CD.
Therefore, we evaluated the transcription signaling pathways and cytokines expression in intestinal mucosa and MAT of active
CD patients. Ten patients with ileocecal CD and eight with noninflammatory diseases were studied. The biopsies of intestinal
mucosa and MAT were snap-frozen and protein expression was determined by immunoblotting. RNA levels were measured by
qPCR. The pIkB/IkB ratio and TNF𝛼 level were significantly higher in intestinal mucosa of CD when compared to controls.
However, STAT1 expression was similar between intestinal mucosa of CD and controls. Considering the MAT, the pIkB/IkB ratio
was significantly lower and the anti-inflammatory cytokine IL10 was significantly higher in CDwhen compared to controls. Finally,
the protein content of pSTAT1 was higher in MAT of CD compared to controls. These findings reinforce the predominance of the
proinflammatory NF-kB pathway in CD intestinal mucosa. For the first time, we showed the activation of STAT1 pathway in MAT
of CD patients, which may help to understand the physiopathology of this immune mediated disease.
1. Introduction
Crohn’s disease (CD) is characterized by mucosal immune
cell activation and cytokine imbalance. The tumor necrosis
factor alfa (TNF𝛼) is one of themost important proinflamma-
tory cytokines involved in this process, and its transcription
depends on the activation of the transcription factor known
as nuclear factor kB (NF-kB) [1]. Besides, some members of
the signal transducer and activator of transcription (STAT)
family have been involved in this process. STAT1 is upregu-
lated in response to interferons and when activated (pSTAT1)
binds to the promoter region of interferon-stimulated genes.
All the transcription factors translocate into the nucleus and
interact with conserved regulatory DNA sequences resulting
in the transcription of genes like chemokines, cytokines,
receptors, signaling regulatory genes, among others. Those
molecules have been studied in several gastrointestinal dis-
orders. However, the most common data about them comes
from analysis of intestinal tissue, rarer than from the mesen-
teric adipose tissue (MAT) nearby the affected intestinal area
[2]. The increase of the MAT is a common feature of the
disease and may involve the small and large bowels; thus
this tissue may represent a relevant role in the pathogenesis
of CD [3, 4]. Histological analyses reveal abnormalities in
the adipose tissue, including infiltration of macrophages
and fibrosis [5]. Adipose tissue is able to release hormones
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which can lead to pro- or anti-inflammatory pathways, such
as leptin that has been shown to increase the secretion of
TNF𝛼 and IL6, as well as activate NF-kB [6, 7] and such as
adiponectin and anti-inflammatory factors which attenuate
the proinflammatory response.
TNF𝛼 has several functions, which are generally coun-
terbalanced by anti-inflammatory pathways, such as IL10.
There is an exacerbation of TNF𝛼 expression alongwith other
inflammatory mediators in the intestinal lamina propria of
the inflammatory bowel diseases (IBD). The intraluminal
stimuli lead to the increased expression of interleukins such
as IL1𝛽, IL6, and IL8, which stimulate the proliferation and
activation of lymphocytes, by a mechanism not completely
understood [8].
Studies of immunological differences between CD and
ulcerative colitis (UC), the two major IBD, have shown
that the activation of NF-kB is more common in CD than
in UC; conversely, expression and activation of STAT1 are
predominantly high in UC. Indeed, STAT1 is activated by an
intracytoplasmic pathway activated by the transmembrane
receptor of IFN𝛾 [9, 10] and can be blocked by SOCS3, which
play an important role in the regulation of this pathway
[11, 12].
This study aimed to investigate if the intestinal mucosa
and MAT of CD patients activate different molecular and
transcriptional pathways, which could lead to different tissue-
specific drugs response in patients and, also, to estab-
lishing potential pharmacologic targets to treat CD. Thus,
we evaluated molecules involved in the activation of NF-
kB and STAT1 pathways and consequent cytokine expres-
sion in intestinal mucosa and MAT of active CD patients.
Finally, the correlation between intestinal mucosa and MAT
of CD patients may help towards a better understand-
ing of the pathophysiology of this chronic inflammatory
disorder.
2. Materials and Methods
2.1. Chemicals and Reagents. All the reagents for SDS-poly-
acrylamide gel electrophoresis and immunoblotting were
from Bio-Rad Laboratories (Richmond, CA, USA). HEPES,
phenylmethylsulfonyl fluoride, aprotinin, dithiothreitol, Tri-
ton X-100, Tween 20, glycerol, and BSA (fraction V) were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Nitrocellulose paper (BA85, 0.2 𝜇m) and the reagents for
chemoluminescence protein labeling in immunoblots were
purchased from Amersham (Aylesbury, UK). The antibodies
against IL10 (sc1783), I𝜅B𝛼 (sc1643), pIkK (sc7977), pSTAT1
(sc7988), TNF𝛼 (sc8301), and SOCS3 (sc7009) were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). IL6 (ab
6672), IL17 (ab 79056), and IL23 (ab45420) antibodies were
from Abcam (Cambridge, MA). The antibody against IL1𝛽
(503502) was obtained from Biolegend (San Diego, CA). The
protein molecular weight was assessed by the PageRulerTM
from Fermentas (Glenburnie, MD). Reagents for real-time
PCR analysis were from Invitrogen (Carlsbad, CA, USA) and
Applied Biosystems (Foster City, CA, USA). Taqman Primers
for TNF𝛼 (Mm00443258_m1), IL1𝛽 (Mm00434228_m1), IL6
(Mm00446190_m1), IL10 (Mm01288386_m1), and glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) (#4352339E)
were obtained fromApplied Biosystems and Integrated DNA
Technologies (IDT).
2.2. Experimental Protocols. Biopsies from intestinal mucosa
(ICD Group) and from mesenteric adipose tissue (ACD
Group) were taken from 10 patients with ileocecal CD who
underwent surgical resection.The presence of disease activity
was assessed by colonoscopy one day before surgery and all
patients had Crohn’s disease activity index (CDAI) [13] more
than 250 points. Patients with CD in other locations were
excluded. The control group of ileal tissue was composed
of eight patients who underwent ileocolonoscopy and the
examination was normal (intestinal mucosa tissue control
group–IC Group). The control group of MAT was composed
of eight patients who underwent rectosigmoidectomy for
noninflammatory disease with normal distal ileum (ileum
mesenteric adipose tissue control group–AC Group). The
study was performed in accordance with the Declaration
of Helsinki and was approved by the Ethical Committee of
the University of Campinas. All samples were taken after
informed consent from the patients. The study was carried
out at the University of Campinas, IBD Research Laboratory
of the Colorectal Surgery Unit, Surgery Department, and
at the Laboratory of Cell Signaling of the Department of
Internal Medicine.
2.3. Western Blot. Biopsies were snap-frozen in liquid nitro-
gen and stored at −80∘C until use. For total protein extract
preparation, the fragments were homogenized in solubilizing
buffer at 4∘C [1% Triton X-100, 100mM Tris-HCl (pH
7.4), 100mM sodium pyrophosphate, 100mM sodium fluo-
ride, 10mM EDTA, 10mM sodium orthovanadate, 2.0mM
phenylmethylsulfonyl fluoride (PMSF), and 0.1mg apro-
tinin/ml] with a Polytron PTA 20S generator (model PT
10/35; Brinkmann Instruments, Westbury, NY) operated at
maximum speed for 30 sec. Insoluble material was removed
by centrifugation (12000 rpm at 4∘C for 40min). The protein
concentration of the supernatants was determined by BCA
method (Pierce BCA Protein Assay Kit. Catalog number
23225). Aliquots of the supernatants containing 50 𝜇g total
proteins were separated by SDS-PAGE, transferred to nitro-
cellulose membranes and blotted with indicated antibodies
as described in the results. Specific bands were labeled
by a chemiluminescence reaction (SuperSignal West Pico
Chemiluminescent Substrate from Pierce Biotechnology, Inc.
Rockford, IL) and quantified by optical densitometry (Un-
Scan-It Program). We have applied Ponceau staining to
check equal loading of gels and membrane transfer (see
Supplementary Figure S1 in SupplementaryMaterial available
online at https://doi.org/10.1155/2017/7646859) [14, 15].
2.4. RNAExtraction andQuantitative Real-Time PCR (qPCR).
Total RNAwas extracted using a commercially available acid-
phenol reagent Trizol (Invitrogen Corp.) according to the
manufacturer’s instructions. The RNA concentration, purity,
and integrity were confirmed spectrophotometrically using a
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Nanodrop (ND-1000; Nanodrop Technologies, Wilmington,
DE). RNA was treated with RNase-free Dnase (RQ1 RNase-
free Dnase, Promega) and then reverse transcribed using
oligo (dT) primers and reverse transcriptase (RevertAid
Kit, Fermentas). The reaction mixture (20𝜇l) was incubated
at 42∘C for 60min and then 10min at 70∘C and cooled on ice.
qPCRwas performed on resulting cDNA, using themanufac-
turer’s protocol. Amplification was performed in a 10 𝜇L final
volume containing 40–50 ng of reverse-transcribed RNA
according to the manufacturer’s recommendations using the
TaqMan PCR master mix.
Real-time PCR amplification consisted of an initial denat-
uration step (50∘C for 2min and 95∘C for 10min), 40 cycles
of denaturation (95∘C for 15 s), annealing (53∘C for 20 s),
and extension (72∘C for 20 s), followed by a final incubation
at 60∘C for 1 minute. All measurements were normalized
by the expression of GAPDH gene, considered as a stable
housekeeping gene. Gene expression was determined using
the delta-delta Ct method [16].
Real-time PCR analysis of gene expression was carried
out in anABI Prism 7500 sequence detection system (Applied
Biosystems). The optimal concentration of complementary
DNA (cDNA) and primers, as well as themaximumefficiency
of amplification, were obtained through five-point, twofold
dilution curve analysis for each gene. Amplification was
performed in a 20 𝜇L final volume containing 40–50 ng of
cDNA according to the manufacturer’s recommendations
using the TaqMan PCR master mix. Real-time data were
analyzed using the Sequence Detector System 1.7 (Applied
Biosystems). Results were expressed as relative transcript
amount as previously optimized [16].
2.5. Histological Analysis: Hematoxylin and Eosin (H&E)
Staining. Biopsies from the intestinalmucosa and fromMAT
near the affected intestinal area were embedded in paraffin
blocks for histological analysis. Sections of 5 𝜇mwere cut and
stained with H&E dye. Photomicrographs were taken using
a Zeiss Axiophot microscope and Cannon Power Shot G5
digital camera system (Cannon Inc., Tokyo). Fields of higher
magnification (20x) were scanned and random fields were
analyzed.
2.6. Statistical Analysis. All results are reported as means ±
SEM. Data were analyzed by the Mann–Whitney Test, com-
paring the MAT of the CD group and its respective adipose
control group and comparing, separately, the intestinal tissue
of the CD group and its respective intestinal control group.
The level of significance was set at 𝑝 < 0.05.
3. Results
3.1. Morphometric Analysis of the Intestinal and MAT of CD
Patients. H&E staining of CD intestinal mucosa showed
thickening of the bowel wall associated with inflammation
and deep linear ulcerations (Figure 1(b)) when compared to
control (Figure 1(a)). In addition, we demonstrated that the
area and the perimeter of the MAT were lower (Figure 1(d))
in CD patients when compared to the control group (Fig-
ure 1(c)).
3.2. Evaluation of the Inflammatory Markers in Intestinal Mu-
cosa of CD Patients. Patients with CD showed increased
mRNA levels of inflammatorymarkers such as IL6, IL8, IL23,
and IL10 (𝑝 < 0.05; Figures 2(a), 2(b), 2(c), and 2(d), resp.)
in the intestinalmucosa when compared to control. However,
no difference in TNF𝛼 gene expression was detected between
ICD and IC groups (Figure 2(e)). On the other hand, the
protein level of TNF𝛼, IL1𝛽, and IL23 (𝑝 < 0.05; Figures
2(f), 2(g), and 2(h), resp.) was significantly higher in the ICD
Group when compared to control.
3.3. Evaluation of the Inflammatory Markers in MAT of CD
Patients. TNF𝛼, IL6, IL8, IL23, and IL10 gene expressions
(Figures 3(a), 3(b), 3(c), 3(d), and 3(e), resp.) were similar
among the MAT groups, as well as protein expressions of
TNF𝛼, IL17, and IL23 (Figures 3(f), 3(g), and 3(h), resp.). The
anti-inflammatory cytokine IL10 was increased in MAT of
CD patients when compared to respective control (𝑝 > 0.05;
Figure 3(i)).
3.4. Modulation of Nuclear Transcription Factors in the In-
testinal Mucosa and MAT of CD Patients. We evaluated the
pIkB/IkB ratio by immunoblotting and it was significantly
higher in the ICD Group when compared to control (𝑝 <
0.05; Figure 4(a)). Conversely, the pIkB/IkB ratio was lower
in MAT of CD patients when compared to control group
(𝑝 > 0.05; Figure 5(a)), showing a different pattern in the
inflammatory signaling response compared to the intestinal
mucosa.
Despite the increased gene expression of STAT1 in the
intestinal mucosa of CD patients compared to control group
(𝑝 < 0.05 Figure 4(c)), no differences in the phosphorylated
and activated form of STAT1 (pSTAT1) were observed among
the groups in intestinal mucosa (Figure 4(b)). Indeed, the
SOCS3 protein, which is a downregulator of STAT pathways,
was also significantly higher in ICD Group when compared
to IC Group (𝑝 < 0.05; Figure 4(d)).
Interestingly, although there were no differences in STAT1
gene expression, the protein content of the activated form of
STAT1 (pSTAT1) was higher in ACD Group compared to AC
Group (𝑝 < 0.05), showing that the STAT1 transcriptional
pathway is activated inMAT of CD patients. Figures 5(c) and
5(b), respectively, illustrate these findings.
4. Discussion
The predominance of NF-kB activation in CD and STAT1
activation in UC has been reported in the literature [9, 10,
17]. Schreiber et al. [9] studied patients with active IBD
and compared the expression and activation of STAT1 in
endoscopic colonic biopsies. They concluded that STAT1
expression and activation are higher in UC compared to
CD and controls. However, there are no studies of STAT1
activation in MAT. Schreiber et al. [10] revealed that NF-kB
activation was detected in intestinal mucosa of both diseases,
CD and UC, but the highest levels were seen in the lamina
propria biopsy samples from CD patients. NF-kB is found in
cytoplasm and is bound to IkB𝛼, which prevents it fromgoing
into the nucleus [18]. Once this signaling pathway is activated,
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Figure 1: Haematoxylin and Eosin (H&E) staining of intestinal mucosa and mesenteric adipose tissues segments of a representative Crohn’s
disease patient. (a) Intestinalmucosa of a normal control subject (ICGroup). (b) Intestinalmucosa of CD patient (ICDGroup), showing crypt
distortion, ulcers, and inflammatory infiltrate. (c) Mesenteric adipose tissue of a normal control subject (AC Group). (d) Mesenteric adipose
tissue of CD patient (ACD Group) revealing characteristic morphometric features, with reduced adipocyte size. Nuclear counterstaining:
Mayer’s haematoxylin. Original magnification ×20.
the protein IkB𝛼 is phosphorylated and degraded by the
ubiquitin-proteasome pathway, releasing the NF-kB, which
binds to specific DNA sequences in the nucleus, activating
target genes involved in the proinflammatory response [18].
In the present study, we show that TNF𝛼 expression and
the NF-kB signaling pathway are activated in the intestinal
mucosa of CD patients when compared to controls, whereas
no differences were observed in STAT1 pathway, as demon-
strated by the lack of pSTAT1 modulation in ICD and IC
groups. This finding can be explained by the increased levels
of SOCS3 in ICD Group, which may inhibit the STAT1
activation [19] and reinforce the predominance of NF-kB
pathway in CD. At least in experimental models [20], NF-kB
inhibitors ameliorate colonic inflammation.
Additionally, several other proinflammatory cytokines
were found to be increased in intestinal mucosa of CD. Fur-
thermore, although higher TNF𝛼 protein levels were noticed
in the intestinal mucosa of CD, no differences were observed
in its transcriptional expression, probably due to increased
stability of the gene promoter [21]. Another possibility is
that high TNF𝛼 protein expression could induce a negative
feedback of TNF𝛼 gene transcription. Conversely, higher
STAT1 gene expression in intestinal mucosa of CD and no
differences in pSTAT1 expression were observed and could
be explained by a higher protein stability and protection from
ubiquitination and degradation outcomes.
The increase of MAT is usually shown as a marker of an
active and more aggressive CD [22–26]. MAT can have an
important role in the maintenance of CD, since the altered
balance between proinflammatory and anti-inflammatory
factors in adipocytes could lead to the activation of the
innate and adaptive immune response [27, 28]. Previous
studies have demonstrated the controversy expression of
important inflammatory markers in MAT of CD patients.
Desreumaux and coworkers published in 1999 a study show-
ing an increased expression of TNF𝛼 in theMAT of the small
bowel mesentery in CD patients, suggesting the adipocytes as
one of the source of TNF𝛼 production [29]. Our results seem
controversial to the literature, once we show no differences
in TNF𝛼 expression, along with decreased NF-kB pathway
activation demonstrated by decreased pIKB/IKB ratio and
increased IL10 expression in MAT of CD patients. Besides,
there were no differences in IL17 and IL23 protein expressions
in this tissue.
Furthermore, a study conducted by Yamamoto and col-
laborators [3] in 2005 showed an increase of adiponectin
secretion and tissue concentration in hypertrophied MAT
of CD patients. Although, in this study, the comparison
was made with normal MAT from IBD patients, differ-
ently of our controls, they concluded that the MAT could
serve as a barrier that prevents the spread of inflammation
into the intra-abdominal space. Conversely, Rodrigues and
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Figure 2: Evaluation of cytokines gene expressions in the intestinal mucosa of Crohn’s disease patients. Inflammatory signaling proteins
reveal a proinflammatory pattern in the intestinal mucosa of Crohn’s disease patients. mRNA levels (qRT-PCR) of IL6 (a), IL8 (b), IL23A (c),
IL10 (d), and TNF𝛼 (e), in intestinal mucosa of CD patients (ICD Group) compared to controls (IC Group). Western blot analysis of TNF𝛼
(f), IL1𝛽 (g), and IL23 (h) in intestinal mucosa of CD patients (ICD Group) compared to controls (IC Group). Each band represents one
patient. For ICD, 𝑛 = 10; for IC, 𝑛 = 8, ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 versus control. TA: transcription amount. ASU: arbitrary
scanning unit.
6 International Journal of Inflammation
AC ACD
0.0
0.5
1.0
1.5
2.0
TN
F훼
 (q
PC
R 
TA
)
(a)
AC ACD
0.0
0.2
0.4
0.6
0.8
1.0
IL
6 
(q
PC
R 
TA
)
(b)
AC ACD
0.0
0.5
1.0
1.5
2.0
IL
8 
(q
PC
R 
TA
)
(c)
AC ACD
0.0
0.5
1.0
1.5
IL
23
A
 (q
PC
R 
TA
)
(d)
AC ACD
0.0
0.5
1.0
1.5
2.0
IL
10
 (q
PC
R 
TA
)
(e)
AC ACD
TNF훼
0
50
100
150
TN
F훼
 (a
su
)
(f)
AC ACD
IL17
0
50
100
150
IL
17
 (a
su
)
(g)
AC ACD
IL23
0
50
100
150
IL
23
 (a
su
)
(h)
AC ACD
IL10
0
50
100
150
IL
10
 (a
su
)
∗∗
(i)
Figure 3: Evaluation of cytokines gene expressions in the mesenteric adipose tissue of Crohn’s disease patients. Inflammatory signaling
pattern in the mesenteric adipose tissue of Crohn’s disease patients. mRNA levels (qRT-PCR) of TNF𝛼 (a), IL6 (b), IL8 (c), IL23A (d), and
IL10 (e) in the mesenteric adipose tissue (MAT) of CD patients (ACD Group) compared to controls (AC Group). Western blot analysis of
TNF𝛼 (f), IL17 (g), IL23 (h), and IL10 (i) in the mesenteric adipose tissue (MAT) of CD patients (ACD Group) compared to controls (AC
Group). Each band represents one patient. For ACD, 𝑛 = 10; for AC, 𝑛 = 8, ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 versus control. TA:
transcription amount. ASU: arbitrary scanning unit.
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Figure 4: Intestinal mucosa of Crohn’s disease patients shows inflammation driven by NF-KB. Higher SOCS3 protein expression
counterbalances the STAT1 activation. Western blot analysis of pI𝜅B/I𝜅B ratio (a), pSTAT1 (b), and SOCS3 (d) in intestinal mucosa of CD
patients (ICD Group) compared to controls (IC Group). mRNA levels (qRT-PCR) of STAT1 (c) in intestinal mucosa of CD patients (ICD
Group) compared to controls (IC Group). Each band represents one patient. For ICD, 𝑛 = 10; for IC, 𝑛 = 8; ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and
∗∗∗𝑝 < 0.001 versus control. ASU: arbitrary scanning unit; TA: transcription amount.
collaborators [30] in 2012 revealed low expression of
adiponectin in MAT of CD patients, which may show a
deficiency in the anti-inflammatory mechanism in intestinal
mesentery near the affected intestinal area during the late
stages of this chronic disease, and this could help to perpet-
uate a state of chronic inflammation. Our results showing
the increased protein levels of IL10 in MAT of CD patients
corroborate with Yamamoto study; however, the controversy
persists.
Additionally, our results showed no differences among
protein and gene expression of TNF𝛼 or other proinflamma-
tory cytokines in AC and ACD groups. Also, the pIkB/IkB
ratio was lower in ACD Group compared to AC Group. No
difference in STAT1 gene expression was observed in MAT;
however the pSTAT1 was higher in MAT of CD patients,
similar to the increase found in UC patients, as reported
in the literature [31]. Although we found higher IL10 and
pSTAT1 protein expression in MAT of CD, there were no
differences in the transcriptional levels. This discrepancy of
transcription and protein levels may be also explained by
an increased stability of the gene promoter or a negative
feedback of IL10 and STAT1 gene transcription induced by
their respective higher protein expressions [21].
The role of MAT is still controversial in the literature
as discussed above. The small diameter of MAT adipocytes
of CD, as seen in severe obese patients, suggests a latent
inflammatory condition inMAT [22].Morphometric features
of the adipocytes from CD MAT were already verified
in the literature [4, 32]. Dias and collaborators [32] also
correlated the lower diameter and area of the adipocytes
with lower apoptosis, which could explain the higher number
of adipocytes per field of higher magnification. Indeed,
they did not find proliferation in this tissue as expected
in nonobese individuals. Mature adipocytes are not able to
do cell division; we can only see adipocyte proliferation in
severe obesity. However, another mechanism that can lead
8 International Journal of Inflammation
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Figure 5: Mesenteric adipose tissue of Crohn’s disease patients shows activation of STAT1 transcriptional pathway. Western blot analysis of
pI𝜅B/I𝜅B ratio (a) and pSTAT1 (b) in the mesenteric adipose tissue (MAT) of CD patients (ACD Group) compared to controls (AC Group).
mRNA levels (qRT-PCR) of STAT1 (c) in MAT of CD patients (ACD Group) when compared to controls (AC Group). Each band represents
one patient. For ACD, 𝑛 = 10; and, for AC, 𝑛 = 8, ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 versus control. ASU: arbitrary scanning unit; TA:
transcription amount.
to adipocyte number increase is by cell differentiation. This
occurs through the adipogenesis pathway initiated by adipose
stem cells [33, 34], which could explain the morphological
and metabolic alterations in CD MAT. Recently, paracrine
functions of the adipose-derived stromal vascular fraction
(AD-SVF) have been studied and heterogeneous populations
of undifferentiated mononuclear elements were also verified
[34, 35]. Thus, in light of our results, it is still hard to confirm
if MAT have an anti-inflammatory role that could attenuate
the inflammation inCDpatients or if amild proinflammatory
response is activated as seen in UC patients. The interaction
between cytokines, adipokines, transcription factors, adipose
stem cells, vascular endothelia, and adipocyte plasticity may
be implicated inMAT remodeling, which certainly influences
CD physiopathology.
Therefore the results of the present study reinforce the
predominance of proinflammatory NF-KB pathway in the
intestinal mucosa of CD patients. Additionally, for the first
time, we showed that the inflammatory status of MAT in
CD is mediated by STAT1 activation. On the other hand,
this activation may lead to increase of anti-inflammatory
cytokines, such as IL10. According to this study, MAT may
play an important role in the pathophysiology and/or activity
of CD. Indeed, the knowledge of the molecular signaling
activated, along with the transcription factors and cytokine
expression in different tissues, such as MAT and intestinal
mucosa, is important to understand the physiopathology of
CD and also to search for new drugs that address tissue-
specific differences.
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